Cancer Genetics Enters Strategic Partnership with Genecast Biotechnology to Commercialize Tissue of Origin Test in China
Cancer Genetics (Nasdaq:CGIX) a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced that it has signed an exclusive distribution agreement with Genecast Biotechnology to market, distribute and sell the Tissue of Origin (TOO) Test in China. As quoted in the press release: John A. Roberts, Chief Executive Officer … Continued
Cancer Genetics (Nasdaq:CGIX) a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced that it has signed an exclusive distribution agreement with Genecast Biotechnology to market, distribute and sell the Tissue of Origin (TOO) Test in China.
As quoted in the press release:
John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, “Genecast Biotechnology has an impressive, well-established menu of tumor DNA testing and gene-based tests, and is the optimal partner to bring our TOO test to the China market. TOO enables identification of tumors of unknown origin. We are excited to make this test available to cancer patients in China through Genecast’s proven distribution capabilities in the space. This collaboration is in line with our business transformation strategy of driving sustainable, long-term growth and profitability by leveraging our unique assets.”
Du Bo, Co-Founder and CEO of Genecast, said, “We are excited to enter this collaboration with CGI. We believe that they offer a host of tests and services that can bring a paradigm change in the precision oncology space. More specifically, CGI’s TOO test has the potential to improve lives of many cancer patients. The focus of this collaboration is to unlock the commercial opportunity of the TOO test in China while providing access to a broader cancer patient population and potentially improving clinical outcomes.”